USBio Logo

C5074 Ciprofloxacin Hydrochloride, Monohydrate CAS: 86393-32-0

Specifications
References
CAS Number
86393-32-0
Grade
Molecular Biology Grade
MDL Number
MFCD00242856
Molecular Formula
C17H18FN3O3•HCl•H2O
Molecular Weight
385.8
EU Commodity Code
38220090
Shipping Temp
RT
Storage Temp
-20°C
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic Acid Hydrochloride; Bay Q3939 Hydrochloride

Ciprofloxacin Hydrochloride is a high activity fluoroquinolone antibiotic effective against a broad spectrum of gram positive and negative bacteria such as Pseudomonas, Salmonella, streptococcus and Staphylococcus. Effective against mycoplasma (12 days). Ciprofloxacin differs from other quinolones in that it has a fluorine atom at the 6-position, a piperazine moiety at the 7-position, and a cyclopropyl ring at the 1-position. The bactericidal action of ciprofloxacin results from interference with the enzyme DNA gyrase which is needed for the synthesis of bacterial DNA. Ciprofloxacin has been shown to be active against most strains of the following organisms
Gram-Positive Bacteria
Enterococcus faecalis (Many strains are only moderately susceptible); Staphylococcus haemolyticus; Staphylococcus hominis; Staphylococcus saprophyticus; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae; Streptococcus pyogenes.
Gram-Negative Bacteria
Acinetobacter calcoaceticus subs. anitratus; Acinetobacter calcoaceticus subs. Iwoffi; Aeromonas caviae; Aeromonas hydrophila; Brucella melitensis; Campylobacter coli; Campylobacter jejuni; Citrobacter diversus; Citrobacter freundii; Edwardsiella tarda; Enterobacter aerogenes; Enterobacter cloacae; Escherichia coli; Haemophilus ducreyi; Haemophilus influenzae; Haemophilus parainfluenzae; Klebsiella oxytoca; Klebsiella pneumoniae; Legionella pneumophila; Moraxella (Branhamella) catarrhalis; Morganella morganii; Neisseria gonorrhoeae; Neisseria meningitidis; Pasteurella multocida; Proteus mirabilis; Proteus vulgaris; Providencia rettgeri; Providencia stuartii; Pseudomonas aeruginosa; Salmonella enteritidis; Salmonella typhi; Serratia marcescens; Shigella flexneri; Shigella sonnei; Vibrio cholerae; Vibrio parahaemolyticus; Vibrio vulnificus; Yersinia enterocolitica.
Other Organisms
Chlamydia trachomatis (only moderately susceptible); Mycobacterium tuberculosis (only moderately susceptible).
Also Available
C5075: Ciprofloxacin Hydrochloride 10mg/ml
Synonyms
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic Acid Hydrochloride; Bay Q3939 Hydrochloride
CAS No
86393-32-0 Free Base: 85721-33-1
Molecular Formula
C17H18FN3O3•HCl•H2O
Molecular Weight
385.8
Purity
98-102%
Appearance
Faintly yellowish to light yellow crystalline powder
pH
3.0-4.5 (The pH for 0.2% infusion solutions is 3.5-4.6).
Heavy Metals
≤0.002%
Loss on Drying
4.7-6.7%
Fluoroquinolonic Acid
≤0.2%
Solubility
Water: 3.5g/dL Methanol: 0.21g/dL Acetic acid: 0.14g/dL Ethanol: 0.016g/dL Water and 0.1M NaOH: Solutions are stable to hydrolysis for 16 hrs. at 90°C. 0.1M HCl: Displays slight decarboxylation. Turbidity can be cleared by heat to 30-50°C
Working Concentration
Effective at low concentrations (10ug/ml) in water and buffered media.
Storage and Stability
Store powder at -20°C. Reconstitute with suitable solvent. Aliquot and store at -20°C. Solutions should be protected from light. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
References
1. Sweeney, L.G. et al. (2005) Int J Pharm. 305:180-185. 2. Mani, N. et al., (2006) Antimicrobial Agents and Chemotherapy 50:1228-1237. 3. Callegan, M.C. et al., (2006) Curr Eye Res. 31:693-702. 4. Hoti, S. et al., (2006) Molecular Therapy (2006) 14:768-778. 5. Ely, L et al., (2007) Eur J Pharm Biopharm. 65:346-353. 6. Hoti, S. et al., (2010) Cancer Gene Therapy 17; 585-597.
USBio References
US Biological application references: 1. Sweeney, L.G. et al. (2005) Int J Pharm. 305:180-185. 2. Mani, N. et al., (2006) Antimicrobial Agents and Chemotherapy 50:1228-1237. 3. Callegan, M.C. et al., (2006) Curr Eye Res. 31:693-702. 4. Hoti, S. et al., (2006) Molecular Therapy (2006) 14:768-778. 5. Ely, L et al., (2007) Eur J Pharm Biopharm. 65:346-353. 6. Hoti, s. et al., (2010) Cancer Gene Therapy 17; 585-597.
Pricing
Order
Proceed to Checkout
Cart Summary
ProductSizeListYour PriceQtyExt Price
Subtotal:Subtotal:
Subtotal:Subtotal:
Total Coupon Savings:Total Coupon Savings:()
Your cart is currently empty.
- Coupon Code
Recently Viewed
  • Contact Us

    Visit our technical library or contact our support staff to answer your questions.

    Telephone:
    1-800-520-3011

    Library | Contact

    Distributors

    For customers outside of the United States, please use one of our many distributors.

    View Distributors

    Payment Methods

    We accept the following payment methods as well as pay-by-invoice.

    MasterCard Visa PayPal
    © 2023-2024 United States Biological - All Rights Reserved